DE60229979D1 - - Google Patents

Info

Publication number
DE60229979D1
DE60229979D1 DE60229979T DE60229979T DE60229979D1 DE 60229979 D1 DE60229979 D1 DE 60229979D1 DE 60229979 T DE60229979 T DE 60229979T DE 60229979 T DE60229979 T DE 60229979T DE 60229979 D1 DE60229979 D1 DE 60229979D1
Authority
DE
Germany
Prior art keywords
methods
polypeptide antigen
peptides
antigen
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60229979T
Other languages
English (en)
Inventor
Mark Larche
Philip William Ledger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Circassia Ltd
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23324613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60229979(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Circassia Ltd filed Critical Circassia Ltd
Application granted granted Critical
Publication of DE60229979D1 publication Critical patent/DE60229979D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
DE60229979T 2001-12-05 2002-12-05 Expired - Lifetime DE60229979D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33838501P 2001-12-05 2001-12-05
PCT/GB2002/005548 WO2003047618A2 (en) 2001-12-05 2002-12-05 Immunotherapeutic methods and systems

Publications (1)

Publication Number Publication Date
DE60229979D1 true DE60229979D1 (de) 2009-01-02

Family

ID=23324613

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229979T Expired - Lifetime DE60229979D1 (de) 2001-12-05 2002-12-05

Country Status (9)

Country Link
US (2) US20060024334A1 (de)
EP (1) EP1453539B1 (de)
JP (2) JP4874522B2 (de)
AT (1) ATE414534T1 (de)
AU (1) AU2002347369A1 (de)
CA (1) CA2469078A1 (de)
DE (1) DE60229979D1 (de)
ES (1) ES2316632T3 (de)
WO (1) WO2003047618A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE414534T1 (de) * 2001-12-05 2008-12-15 Circassia Ltd Immunotherapeutische methoden und systeme
US7279295B2 (en) * 2002-03-27 2007-10-09 Phadia Ab Allergen
WO2003096869A2 (en) * 2002-05-16 2003-11-27 Alk Abelló A/S Recombinant bet. v. 1. allergen mutants, methods and process thereof
GB0307989D0 (en) * 2003-04-07 2003-05-14 Mcewen Lab Ltd Therapeutic composition
JP2007505911A (ja) * 2003-09-17 2007-03-15 ベイビー・ブースト，インコーポレイテッド アレルギーを予防する方法および装置
DE10351471A1 (de) * 2003-11-04 2005-06-09 Ursula Prof. Dr. Wiedermann-Schmidt Polyvalente Allergievakzine
MXPA06014769A (es) * 2004-06-17 2007-03-26 Mannkind Corp Eficiencia mejorada de la inmunoterapia al integrar metodos de diagnostico con terapeuticos.
CN100374152C (zh) 2005-12-23 2008-03-12 中国农业大学 一种过敏性反应抑制剂
JP2007189919A (ja) * 2006-01-17 2007-08-02 Osaka Prefecture Univ イヌアレルギーに対する予防又は治療作用を有するポリペプチド
JP2007189920A (ja) * 2006-01-17 2007-08-02 Osaka Prefecture Univ イヌアレルギーに対する予防又は治療作用を有するポリペプチド
EP2423222B2 (de) 2007-01-30 2020-07-29 Epivax, Inc. Regulatorische T-Zellen-Epitopen sowie Zusammensetzungen damit und Anwendungen davon
KR20090104133A (ko) * 2007-01-30 2009-10-05 알크-아벨로 에이/에스 제2 집먼지 진드기 2군 알레르겐에 대한 알레르기를 치료하기 위한 제1 집먼지 진드기 2군 알레르겐의 용도
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
AU2013202871B2 (en) * 2007-06-01 2015-10-22 Circassia Limited Vaccine peptide combinations against cat allergy
WO2009022154A2 (en) * 2007-08-15 2009-02-19 Circassia Limited Peptide with multiple epitopes
ES2378870T5 (es) 2008-08-15 2016-02-03 Circassia Limited Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía
WO2010018384A1 (en) * 2008-08-15 2010-02-18 Circassia Limited T-cell antigen peptide from allergen for stimulation of il-10 production
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
PT2367561E (pt) 2008-11-30 2015-10-23 Immusant Inc Composições e métodos para o tratamento da doença celíaca
WO2010089554A1 (en) 2009-02-05 2010-08-12 Circassia Limited Peptides for vaccine
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
WO2011106645A1 (en) * 2010-02-26 2011-09-01 Benaroya Research Institute Direct analysis of antigen-specific immune response
WO2011112788A1 (en) * 2010-03-12 2011-09-15 Antigen Laboratories, Inc. Methods of treating allergies with substantially phenol-free carriers
JP6062851B2 (ja) * 2010-04-30 2017-01-18 アロヴェイト・エルエルシー 口腔粘膜を介してアレルギーを減感作するための方法、物品及びキット
EP2681555B1 (de) 2011-02-25 2020-04-08 Benaroya Research Institute Allergienachweis
EP2524701A3 (de) * 2011-05-20 2012-12-19 Nitto Denko Corporation Pharmazeutische Zusammensetzung und Herstellungsverfahren dafür
US11421006B2 (en) 2012-05-03 2022-08-23 La Jolla Institute For Allergy And Immunology T cell epitopes from Cockroach and methods of making and using same
GB201208293D0 (en) * 2012-05-11 2012-06-20 Circassia Ltd Hydrochlorice salt of peptide
DK2914286T3 (da) 2012-10-30 2021-11-08 Aravax Pty Ltd Hidtil ukendte immunterapeutiske molekyler og anvendelser deraf
JP2014028820A (ja) * 2013-08-30 2014-02-13 China Agricultural Univ アレルギー抑制剤の組成物及びキットならびにその使用方法
AU2014318889B2 (en) 2013-09-10 2020-02-20 Immusant, Inc. Dosage of a gluten peptide composition
US10485867B2 (en) 2013-09-19 2019-11-26 Allovate, Llc Toothpaste for delivery of allergens to oral mucosa
EP3049098A4 (de) 2013-09-25 2017-08-16 Aravax Pty Ltd Neuartige immuntherapeutische zusammensetzung und verwendungen davon
EP3062772B1 (de) * 2014-03-18 2018-01-24 APEPTICO Forschung und Entwicklung GmbH Peptidmedikament in der form eines trockenpulvers
US10872313B2 (en) 2015-06-02 2020-12-22 ROCA Medical Ltd. Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
EP3201354A1 (de) 2014-09-29 2017-08-09 Immusant Inc. Verwendung eines genetischen hla status zur beurteilung oder auswahl der behandlung von zöliakie
US10548974B2 (en) 2015-06-02 2020-02-04 ROCA Medical Ltd. Therapeutic treatment kit for allergies based on DNA profiles
US10369215B2 (en) 2015-06-02 2019-08-06 ROCA Medical Ltd. Predilution sets for distributing antigens
US20160362205A1 (en) * 2015-06-02 2016-12-15 ROCA Medical Ltd. Use of autoinjector for distributing antigens to the public
US20170021010A1 (en) * 2015-07-21 2017-01-26 David Phillip ERSTEIN Allergy preventing dosage controlled food packets
JP7041923B2 (ja) * 2016-03-03 2022-03-25 学校法人藤田学園 大豆アレルギーの抗原
CN108265057B (zh) * 2016-12-31 2019-10-18 江苏众红生物工程创药研究院有限公司 一种重组户尘螨2类变应原蛋白及其制备方法和应用
CN108265059B (zh) * 2016-12-31 2021-01-05 江苏众红生物工程创药研究院有限公司 一种重组粉尘螨2类变应原蛋白及其制备方法与应用
CN113336862B (zh) * 2021-07-05 2022-03-01 广东省科学院动物研究所 一种抗多发性硬化的重组蛋白及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358710A (en) * 1989-12-01 1994-10-25 Alec Sehon Method for the suppression of an immune response
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
WO1995026980A2 (en) * 1994-04-01 1995-10-12 Immulogic Pharmaceutical Corporation Haptenated peptides and uses thereof
EP1044019A1 (de) * 1998-01-09 2000-10-18 Circassia Limited Methoden und zusammensetzungen zur desensibilisierung
ATE414534T1 (de) * 2001-12-05 2008-12-15 Circassia Ltd Immunotherapeutische methoden und systeme

Also Published As

Publication number Publication date
ATE414534T1 (de) 2008-12-15
AU2002347369A8 (en) 2003-06-17
ES2316632T3 (es) 2009-04-16
JP2009292838A (ja) 2009-12-17
AU2002347369A1 (en) 2003-06-17
WO2003047618A2 (en) 2003-06-12
US20110142867A1 (en) 2011-06-16
WO2003047618A3 (en) 2004-01-08
JP4874522B2 (ja) 2012-02-15
JP2005518367A (ja) 2005-06-23
CA2469078A1 (en) 2003-06-12
US20060024334A1 (en) 2006-02-02
EP1453539B1 (de) 2008-11-19
EP1453539A2 (de) 2004-09-08

Similar Documents

Publication Publication Date Title
DE60229979D1 (de)
HUP9901109A2 (hu) Immunogén peptidek vakcinálásra és allergia kezelésére
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
WO2002072636A8 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
AU2001295673A1 (en) Vaccine composition
HUP0105490A2 (hu) Az IgE C-epszilon-3 vagy C-epszilon-4 doménjéből származtatott epitópok és mimotópok, antagonistáik és terápiás alkalmazásuk
NO20050066L (no) Pegylert T20 polypeptid
WO2005067460A3 (en) Epha2 vaccines
WO2007145760A3 (en) Anthrax compositions and methods of use and production
HK1064936A1 (en) Use of polyclonal anti-hiv goat serum as a therapeutic agent
EP1556513A4 (de) Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
AU5423898A (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
ATE360642T1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
EP0955366A4 (de) Antigenes protein aus malassezia
EP1801123A3 (de) Kristalle von ganzen Antikörpern und Fragmenten davon und Verfahren zu ihrer Herstellung und Verwendung
MX2021007047A (es) Formulaciones de anticuerpos.
AU2003241127A1 (en) MEMBRANE-ANCHORED Beta2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES
HUP0200049A2 (en) Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
HK1025220A1 (en) Novel saponin compositions and uses thereof
PL379549A1 (pl) Autologiczne, indukujące tolerancję na antygeny własne komórki pochodzenia monocytarnego oraz ich zastosowanie w preparatach farmaceutycznych
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
MY143402A (en) Preparations used in the treatment and prophilaxis of mycobacterial infections
ATE420890T1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide
WO2002048175A3 (en) Mhc class i associated peptides for prevention and treatment of tuberculosis
MX2021007074A (es) Péptidos basados en laberintina para inmunoterapias contra el cáncer y su uso.

Legal Events

Date Code Title Description
8363 Opposition against the patent